Immuno-oncology for Gynecologic Malignancies.
Immuno-oncology for Gynecologic Malignancies. Adv Exp Med Biol. 2020;1244:149-182 Authors: How J, Patel A, Jazaeri A Abstract Patients with advanced and/or recurrent gynecologic cancers derive limited benefit from currently available cytotoxic and targeted therapies. Successes of immunotherapy in other difficult-to-treat malignancies such as metastatic melanoma and advanced lung cancer have led to intense interest in clinical testing of these treatments in patients with gynecologic cancers. Currently, in the realm of gynecologic oncology, the FDA-approved use of immune checkpoint inhibitors is limited to microsatellite instable cancers and PD-L1-positive cervical cancer. However, there has been an exponential growth of clinical trials testing immunotherapy approaches, both alone and in combination with chemotherapy and/or targeted agents, in patients with gynecologic cancers. This chapter reviews some of the major reported and ongoing immunotherapy clinical trials in patients with endometrial, cervical, and epithelial ovarian cancer. PMID: 32301014 [PubMed - in process]
Publication date: Available online 11 July 2020Source: Journal of Global Antimicrobial ResistanceAuthor(s): Ermira Tartari, Joost Hopman, Benedetta Allegranzi, Bin Gao, Andreas Widmer, Vincent Chi-Chung Cheng, Shuk Ching Wong, Kalisvar Marimuthu, Folasade Ogunsola, Andreas Voss, on behalf of the International Society of Antimicrobial Chemotherapy Infection Prevention Control Working Group, (ISAC-IPC)
Publication date: 30 August 2020Source: International Journal of Pharmaceutics, Volume 586Author(s): Sujuan Zhang, Yongtai Zhang, Zhi Wang, Teng Guo, Xuefeng Hou, Zhiyuan He, Zehui He, Lina Shen, Nianping Feng
Publication date: Available online 10 July 2020Source: Seminars in Cancer BiologyAuthor(s): Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, Doriana Fruci, Federica Gemignani
Publication date: Available online 10 July 2020Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Yan Zhao, Ya-Ni Zhang, Kai-Ting Wang, Lei Chen
Publication date: Available online 10 July 2020Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Angana Biswas, Yetirajam Rajesh, Pralay Mitra, Mahitosh Mandal
Publication date: December 2020Source: Nano Today, Volume 35Author(s): Ling-xiao Zhang, Xia-mei Sun, Ying-bo Jia, Xiao-ge Liu, Mingdong Dong, Zhi Ping Xu, Rui-tian Liu
é R, Jakab A Abstract Endometrial cancer is the most common gynecological malignancy with a relatively good overall prognosis. It traditionally has two subtypes: type 1 (endometrioid carcinoma) and type 2 (non-endometrioid carcinoma). The prognosis is excellent for stage I endometrioid cancer, with a 5-year survival rate of 96%. However, the prognosis is much worse for women with high-risk endometrial cancer. Effective preoperative staging is important in order to tailor treatment and achieve optimal long-term survival. The majority of asymptomatic polyps detected by ultrasound are treated surgically. Conve...
CONCLUSION: According to the results of the specificity tests, the designed aptasensor did not show any significant interactions with other analytes in real samples. Clinical functionality of the aptasensor was appraised in serum samples of healthy individuals and patients examining the PSA level through the fabricated aptasensor and the reference methods. Both methods are comparable in sensitivity. The present fabricated PSA aptasensor with substantial characteristics of ultra- sensitivity and cost-effectiveness can be conventionally built and used for the routine check-up of the men for prostate problems. PMID: 3264...
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing